Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Identification and Management.

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Identification and Management. Expert Rev Clin Immunol. 2020 Aug 08;: Authors: Williams SG, Mollaeian A, Katz JD, Gupta S Abstract INTRODUCTION: Immune checkpoint inhibitors (ICIs) have proved to be groundbreaking in the field of oncology and immunotherapy. However, immune system overactivation from ICIs has introduced a novel medical entity known as immune related adverse events (irAEs), that can affect any organ or tissue. ICI-induced inflammatory arthritis (ICI-IIA) is the most common musculoskeletal irAE and can lead to significant morbidity and limitation in anti-cancer therapy. AREAS COVERED: In this Review the authors focus on ICI-IIA. Relevant articles were identified through PubMed searches, spanning 2010 to the present. The authors detail their current understanding of its pathogenesis, diagnostic evaluation, and management strategies. EXPERT OPINION: ICI-IIA is a complex type of irAE that we are just beginning to tease apart mechanistically and pathologically. It often presents later in the disease course than other irAEs and, due to various reasons, it is under-recognized. In some patients, ICI-IIA may become a chronic disease, which distinguishes it from most irAEs that resolve rapidly after ICI discontinuation. Multiple important questions still demand further research including: which patients may develop ICI-IIA? what are possible diagnostic a...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research